The introduction of PSMA labelled with 68
Ga or 18
F has revolutionized prostate cancer imaging. PSMA PET/CT outperforms in many instances standard imaging; it allows complete evaluation of the local tumor and lymph nodes, visceral and bone metastases with high accuracy in only one examination.
IBA offers you to attend to a free webinar presented by 2 leading figures of Nuclear Medicine: Prof. Stefano Fanti and Dr Horacio Amaral. They will give a very instructive presentations about applications on PSMA PET/CT in prostate cancer.
- 68Ga-PSMA-11 and 18F-PSMA-1007 First Clinical Experiences on Prostate Cancer Patients
, 4-5 pm CET
What will you learn from the webinar ?
- Clinical applications on 68Ga-PSMA-11 in prostate cancer
By Stefano Fanti, Professor of Diagnostic Imaging and Director of Nuclear Medicine Division & PET Unit at the S.Orsola Policlinic Hospital, Italy.
Prof. Fanti will give an overview of the clinical application with 68Ga-PSMA. You will learn the role of 68Ga-PSMA-11 in staging, in recurrence setting, in therapy management and theranostic approach.
By Dr. Horacio Amaral, President of PositronPharma and Director Nuclear Medicine PositronMed- Oncology Clinic Arturo Lopez Perez Foundation (FALP), Chile
Dr. Amaral will share his experience with both 68Ga-PSMA-11 and 18F-PSMA-1007.
The presentation will focus on the comparison from the clinical perspective between the most used PSMA compound: 68Ga-PSMA and the most recent 18F version:, 18F-PSMA -1007.